We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+39.65%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.14B
AUM Growth
+$662M
Cap. Flow
+$228M
Cap. Flow %
10.65%
Top 10 Hldgs %
66.06%
Holding
37
New
6
Increased
15
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$137M
2
ARGX icon
argenx
ARGX
+$75.1M
3
IRON icon
Disc Medicine
IRON
+$57M
4
ASND icon
Ascendis Pharma A/S
ASND
+$35.1M
5
ACLX
Arcellx
ACLX
+$31.8M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$69.4M
2
INCY icon
Incyte
INCY
+$52.7M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$34.7M
4
TGTX icon
TG Therapeutics
TGTX
+$16.8M
5
VRNA
Verona Pharma
VRNA
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VOR icon
26
Vor Biopharma
VOR
$1.21B
$14.5M 0.68%
322,865
-208
-0.1% -$8.58K
CRGX
27
DELISTED
CARGO Therapeutics
CRGX
$7.72M 0.36%
+333,333
New +$5.65M
ZNTL icon
28
Zentalis Pharmaceuticals
ZNTL
$347M
$6.06M 0.28%
+400,000
New +$5.84M
JBIO
29
Jade Biosciences
JBIO
$1.3B
$3.24M 0.15%
+4,092
New +$2.09M
AMAM
30
CALL
DELISTED
Ambrx Biopharma Inc
AMAM
$2.14M 0.1%
150,000
-59,600
-28% -$677K
COGT icon
31
Cogent Biosciences
COGT
$7.32B
– –
-225,605
Closed -$2.2M
ETNB
32
CALL
DELISTED
89bio
ETNB
– –
-329,100
Closed -$5.08M
INCY icon
33
Incyte
INCY
$24.4B
– –
-912,497
Closed -$52.7M
ROIV icon
34
Roivant Sciences
ROIV
$25B
– –
-1,081,767
Closed -$12.6M
SNDX icon
35
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-2,390,077
Closed -$34.7M
UTHR icon
36
United Therapeutics
UTHR
$22B
– –
-307,314
Closed -$69.4M
VRNA
37
DELISTED
Verona Pharma
VRNA
– –
-926,432
Closed -$15.1M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SMFG
Sumitomo Mitsui Financial Group Tokyo, Japan $4.94B AUM 1.39% 1-Year Est. Return

Paradigm Biocapital Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Paradigm Biocapital Advisors held 37 positions worth $2.14B, up 45% from $1.47B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Paradigm Biocapital Advisors deployed $228M of net new capital in Q4 2023, opening 6 new positions and adding to 15 existing holdings. Its largest new stake was Ascendis Pharma A/S: 351,700 shares worth $44.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was TG Therapeutics, an estimated $16.8M trimmed.

  • Paradigm Biocapital Advisors's largest Q4 2023 buy was Ascendis Pharma A/S: 351,700 shares worth $44.3M.
  • Paradigm Biocapital Advisors added most to Nuvalent in Q4 2023, an estimated $137M increase.
  • Paradigm Biocapital Advisors's biggest Q4 2023 reduction was TG Therapeutics, cutting an estimated $16.8M.
  • Paradigm Biocapital Advisors fully exited United Therapeutics in Q4 2023, selling an estimated $69.4M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 66% of its $2.14B portfolio in Q4 2023.
  • Paradigm Biocapital Advisors opened 6 new positions and closed 7 in Q4 2023.
  • Paradigm Biocapital Advisors's portfolio value rose 45% quarter-over-quarter to $2.14B.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.